|
1
|
Coricovac D, Dehelean C, Moaca EA, Pinzaru
I, Bratu T, Navolan D and Boruga O: Cutaneous melanoma-A long road
from experimental models to clinical outcome: A review. Int J Mol
Sci. 19:E15662018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roukos DH: PLX4032 and melanoma:
Resistance, expectations and uncertainty. Expert Rev Anticancer
Ther. 11:325–328. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsai J, Lee JT, Wang W, Zhang J, Cho H,
Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al: Discovery of
a selective inhibitor of oncogenic B-Raf kinase with potent
antimelanoma activity. Proc Natl Acad Sci USA. 105:3041–3046. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eggermont AM, Spatz A and Robert C:
Cutaneous melanoma. Lancet. 383:816–827. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adams BD, Parsons C, Walker L, Zhang WC
and Slack FJ: Targeting noncoding RNAs in disease. J Clin Invest.
127:761–771. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moreno-Moya JM, Vilella F and Simón C:
MicroRNA: Key gene expression regulators. Fertil Steril.
101:1516–1523. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Su Z, Yang Z, Xu Y, Chen Y and Yu Q:
MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget.
6:8474–8490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou K, Liu M and Cao Y: New insight into
microRNA functions in cancer: Oncogene-microRNA-tumor suppressor
gene network. Front Mol Biosci. 4:462017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wozniak M, Mielczarek A and Czyz M: miRNAs
in melanoma: Tumor suppressors and oncogenes with prognostic
potential. Curr Med Chem. 23:3136–3153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Z, Zheng C, Jiang K, He J, Cao X and
Wu S: MicroRNA-503 suppresses cell proliferation and invasion in
osteosarcoma via targeting insulin-like growth factor 1 receptor.
Exp Ther Med. 14:1547–1553. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu L, Xu Q, Li X and Zhang X: MicroRNA-21
regulates the proliferation and apoptosis of cervical cancer cells
via tumor necrosis factor-α. Mol Med Rep. 16:4659–4663. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Markopoulos GS, Roupakia E, Tokamani M,
Vartholomatos G, Tzavaras T, Hatziapostolou M, Fackelmayer FO,
Sandaltzopoulos R, Polytarchou C and Kolettas E:
Senescence-associated microRNAs target cell cycle regulatory genes
in normal human lung fibroblasts. Exp Gerontol. 96:110–122. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qin W, Rong X, Dong J, Yu C and Yang J:
miR-142 inhibits the migration and invasion of glioma by targeting
Rac1. Oncol Rep. 38:1543–1550. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo W, Wang H, Yang Y, Guo S, Zhang W, Liu
Y, Yi X, Ma J, Zhao T, Liu L, et al: Down-regulated miR-23a
contributes to the metastasis of cutaneous melanoma by promoting
autophagy. Theranostics. 7:2231–2249. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bai M, Zhang M, Long F, Yu N, Zeng A and
Zhao R: Circulating microRNA-194 regulates human melanoma cells via
PI3K/AKT/FoxO3a and p53/p21 signaling pathway. Oncol Rep.
37:2702–2710. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo S, Guo W, Li S, Dai W, Zhang N, Zhao
T, Wang H, Ma J, Yi X, Ge R, et al: Serum miR-16: A potential
biomarker for predicting melanoma prognosis. J Invest Dermatol.
136:985–993. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang X and Wu X: miRNA expression profile
of vulvar squamous cell carcinoma and identification of the
oncogenic role of miR-590-5p. Oncol Rep. 35:398–408. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou L, Zhao LC, Jiang N, Wang XL, Zhou
XN, Luo XL and Ren J: MicroRNA miR-590-5p inhibits breast cancer
cell stemness and metastasis by targeting SOX2. Eur Rev Med
Pharmacol Sci. 21:87–94. 2017.PubMed/NCBI
|
|
21
|
Wang L, Shi S, Zhou Y, Mu X, Han D, Ge R
and Mu K: miR-590-5p inhibits A375 cell invasion and migration in
malignant melanoma by directly inhibiting YAP1 expression. Xi Bao
Yu Fen Zi Mian Yi Xue Za Zhi. 33:326–330. 2017.(In Chinese).
PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Workman P, Aboagye EO, Balkwill F, Balmain
A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA,
Glennie MJ, et al: Guidelines for the welfare and use of animals in
cancer research. Br J Cancer. 102:1555–1577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 2015. View Article : Google Scholar
|
|
25
|
Chen K and Rajewsky N: Natural selection
on human microRNA binding sites inferred from SNP data. Nat Genet.
38:1452–1456. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Enright AJ, John B, Gaul U, Tuschl T,
Sander C and Marks DS: MicroRNA targets in Drosophila. Genome Biol.
5:R12003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Legras A, Pécuchet N, Imbeaud S, Pallier
K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F,
Laurent-Puig P and Blons H: Epithelial-to-mesenchymal transition
and MicroRNAs in lung cancer. Cancers. 9:E1012017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Varamo C, Occelli M, Vivenza D, Merlano M
and Nigro Lo C: MicroRNAs role as potential biomarkers and key
regulators in melanoma. Genes Chromosomes Cancer. 56:3–10. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deng Z, Hao J, Lei D, He Y, Lu L and He L:
Pivotal MicroRNAs in melanoma: A mini-review. Mol Diagn Ther.
20:449–455. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grignol V, Fairchild ET, Zimmerer JM,
Lesinski GB, Walker MJ, Magro CM, Kacher JE, Karpa VI, Clark J,
Nuovo G, et al: miR-21 and miR-155 are associated with mitotic
activity and lesion depth of borderline melanocytic lesions. Br J
Cancer. 105:1023–1029. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Satzger I, Mattern A, Kuettler U,
Weinspach D, Niebuhr M, Kapp A and Gutzmer R: microRNA-21 is
upregulated in malignant melanoma and influences apoptosis of
melanocytic cells. Exp Dermatol. 21:509–514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
del Campo Martin SE, Latchana N, Levine
KM, Grignol VP, Fairchild ET, Jaime-Ramirez AC, Dao TV, Karpa VI,
Carson M, Ganju A, et al: MiR-21 enhances melanoma invasiveness via
inhibition of tissue inhibitor of metalloproteinases 3 expression:
In vivo effects of MiR-21 inhibitor. PloS One. 10:e01159192015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang J, Lu L, Xiong Y, Qin W, Zhang Y,
Qian Y, Jiang H and Liu W: MLK3 promotes melanoma proliferation and
invasion and is a target of microRNA-125b. Clin Exp Dermatol.
39:376–384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kappelmann M, Kuphal S, Meister G,
Vardimon L and Bosserhoff AK: MicroRNA miR-125b controls melanoma
progression by direct regulation of c-Jun protein expression.
Oncogene. 32:2984–2991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alegre E, Sanmamed MF, Rodriguez C,
Carranza O, Martin-Algarra S and Gonzalez A: Study of circulating
microRNA-125b levels in serum exosomes in advanced melanoma. Arch
Pathol Lab Med. 138:828–832. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ou C, Sun Z, Li X, Li X, Ren W, Qin Z,
Zhang X, Yuan W, Wang J, Yu W, et al: MiR-590-5p, a
density-sensitive microRNA, inhibits tumorigenesis by targeting
YAP1 in colorectal cancer. Cancer Lett. 399:53–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou Q, Zhu Y, Wei X, Zhou J, Chang L, Sui
H, Han Y, Piao D, Sha R and Bai Y: MiR-590-5p inhibits colorectal
cancer angiogenesis and metastasis by regulating nuclear factor
90/vascular endothelial growth factor A axis. Cell Death Dis.
7:e24132016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chu Y, Ouyang Y, Wang F, Zheng A, Bai L,
Han L, Chen Y and Wang H: MicroRNA-590 promotes cervical cancer
cell growth and invasion by targeting CHL1. J Cell Biochem.
115:847–853. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xiao X, Tang C, Xiao S, Fu C and Yu P:
Enhancement of proliferation and invasion by MicroRNA-590-5p via
targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res.
20:537–544. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shen B, Yu S, Zhang Y, Yuan Y, Li X, Zhong
J and Feng J: miR-590-5p regulates gastric cancer cell growth and
chemosensitivity through RECK and the AKT/ERK pathway. Onco Targets
Ther. 9:6009–6019. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shan X, Miao Y, Fan R, Qian H, Chen P, Liu
H, Yan X, Li J and Zhou F: MiR-590-5P inhibits growth of HepG2
cells via decrease of S100A10 expression and inhibition of the Wnt
pathway. Int J Mol Sci. 14:8556–8569. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang X, Xiang G, Wang Y, Zhang L, Yang X,
Cao L, Peng H, Xue P and Chen D: MicroRNA-590-5p regulates
proliferation and invasion in human hepatocellular carcinoma cells
by targeting TGF-β RII. Mol Cells. 33:545–551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the Roots of Cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zanconato F, Battilana G, Cordenonsi M and
Piccolo S: YAP/TAZ as therapeutic targets in cancer. Curr Opin
Pharmacol. 29:26–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shibata M, Ham K and Hoque MO: A time for
YAP1: Tumorigenesis, immunosuppression and targeted therapy. Int J
Cancer. Apr 26–2018.(Epub ahead of print). doi: 10.1002/ijc.31561.
View Article : Google Scholar
|
|
46
|
Seo WI, Park S, Gwak J, Ju BG, Chung JI,
Kang PM and Oh S: Wnt signaling promotes androgen-independent
prostate cancer cell proliferation through up-regulation of the
hippo pathway effector YAP. Biochem Biophys Res Commun.
486:1034–1039. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee HJ, Diaz MF, Price KM, Ozuna JA, Zhang
S, Sevick-Muraca EM, Hagan JP and Wenzel PL: Fluid shear stress
activates YAP1 to promote cancer cell motility. Nat Commun.
8:141222017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Strnadel J, Choi S, Fujimura K, Wang H,
Zhang W, Wyse M, Wright T, Gross E, Peinado C, Park HW, et al:
eIF5A-PEAK1 signaling regulates YAP1/TAZ protein expression and
pancreatic cancer cell growth. Cancer Res. 77:1997–2007. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fan Y, Gao Y, Rao J, Wang K, Zhang F and
Zhang C: YAP-1 promotes tregs differentiation in hepatocellular
carcinoma by enhancing TGFBR2 transcription. Cell Physiol Biochem.
41:1189–1198. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lee K, Lee KB, Jung HY, Yi NJ, Lee KW, Suh
KS and Jang JJ: The correlation between poor prognosis and
increased yes-associated protein 1 expression in keratin 19
expressing hepatocellular carcinomas and cholangiocarcinomas. BMC
Cancer. 17:4412017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hu X, Chen J and Fu Q: Downregulation of
YAP in clear cell renal cell carcinoma contributes to poor
prognosis and progressive features. Ann Clin Lab Sci. 47:36–39.
2017.PubMed/NCBI
|
|
52
|
Lamar JM, Stern P, Liu H, Schindler JW,
Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes
metastasis through its TEAD-interaction domain. Proc Natl Acad Sci
USA. 109:E2441–E2450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Menzel M, Meckbach D, Weide B, Toussaint
NC, Schilbach K, Noor S, Eigentler T, Ikenberg K, Busch C,
Quintanilla-Martinez L, et al: In melanoma, Hippo signaling is
affected by copy number alterations and YAP1 overexpression impairs
patient survival. Pigment Cell Melanoma Res. 27:671–673. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yuan H, Liu H, Liu Z, Zhu D, Amos CI, Fang
S, Lee JE and Wei Q: Genetic variants in Hippo pathway genes YAP1,
TEAD1 and TEAD4 are associated with melanoma-specific survival. Int
J Cancer. 137:638–645. 2015. View Article : Google Scholar : PubMed/NCBI
|
